A. M. Mora Blázquez

Resource use and healthcare costs in patients with overactive bladder who initiate treatment with mirabegron or antimuscarinic monotherapy in Catalonia: the MIRACAT study.

P. J. Covernton, R. Martins de Almeida, L. Mateu Arrom, 2022, Actas urologicas espanolas.

A retrospective analysis comparing persistence and adherence to treatment with free‐ vs fixed‐dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain

M. Landeira, P. J. Covernton, J. Medina-Polo, 2020, International journal of clinical practice.